Literature DB >> 28636400

Click Biotinylation of PLGA Template for Biotin Receptor Oriented Delivery of Doxorubicin Hydrochloride in 4T1 Cell-Induced Breast Cancer.

Yuvraj Singh1, K K Durga Rao Viswanadham1, Arun Kumar Jajoriya2, Jaya Gopal Meher1, Kavit Raval1, Swati Jaiswal3, Jayant Dewangan4, H K Bora5, Srikanta Kumar Rath4, Jawahar Lal3, Durga Prasad Mishra2, Manish K Chourasia1.   

Abstract

PLGA was functionalized with PEG and biotin using click chemistry to generate a biotin receptor targeted copolymer (biotinylated-PEG-PLGA) which in turn was used to fabricate ultrafine nanoparticles (BPNP) of doxorubicin hydrochloride (DOX) for effective delivery in 4T1 cell induced breast cancer. However, adequate entrapment of a hydrophilic bioactive like DOX in a hydrophobic polymer system made of PLGA is not usually possible. We therefore modified a conventional W/O/W emulsion method by utilizing NH4Cl in the external phase to constrain DOX in dissolved polymer phase by suppressing DOX's inherent aqueous solubility as per common ion effect. This resulted in over 8-fold enhancement in entrapment efficiency of DOX inside BPNP, which otherwise is highly susceptible to leakage due to its relatively high aqueous solubility. TEM and DLS established BPNP to be sized below 100 nm, storage stability studies showed that BPNP were stable for one month at 4 °C, and in vitro release suggested significant control in drug release. Extensive in vitro and in vivo studies were conducted to propound anticancer and antiproliferative activity of BPNP. Plasma and tissue distribution study supplemented by pertinent in vivo fluorescence imaging mapped the exact fate of DOX contained inside BPNP once it was administered intravenously. A comparative safety profile via acute toxicity studies in mice was also generated to out rightly establish usefulness of BPNP. Results suggest that BPNP substantially enhance anticancer activity of DOX while simultaneously mitigating its toxic potential due to altered spatial and temporal presentation of drug and consequently deserve further allometric iteration.

Entities:  

Keywords:  PLGA; active targeting; click chemistry; common ion effect; doxorubicin hydrochloride; nanoparticles

Mesh:

Substances:

Year:  2017        PMID: 28636400     DOI: 10.1021/acs.molpharmaceut.7b00310

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  In Vivo Pharmacokinetics Assessment of Indocyanine Green-Loaded Nanoparticles in Tumor Tissue with a Dynamic Diffuse Fluorescence Tomography System.

Authors:  Yanqi Zhang; Limin Zhang; Guoyan Yin; Wenjuan Ma; Jiao Li; Zhongxing Zhou; Feng Gao
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Fast functionalization of ultrasound microbubbles using strain promoted click chemistry.

Authors:  Xifeng Liu; Ping Gong; Pengfei Song; Feng Xie; A Lee Miller Ii; Shigao Chen; Lichun Lu
Journal:  Biomater Sci       Date:  2018-02-27       Impact factor: 6.843

Review 3.  Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy.

Authors:  Ki-Taek Kim; Jae-Young Lee; Dae-Duk Kim; In-Soo Yoon; Hyun-Jong Cho
Journal:  Pharmaceutics       Date:  2019-06-14       Impact factor: 6.321

4.  Chlorin e6-Biotin Conjugates for Tumor-Targeting Photodynamic Therapy.

Authors:  Wei Liu; Xingqun Ma; Yingying Jin; Jie Zhang; Yang Li; Yuxia Tang; Yong Song; Shouju Wang
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

Review 5.  Drug-loaded PEG-PLGA nanoparticles for cancer treatment.

Authors:  Dan Zhang; Lin Liu; Jian Wang; Hong Zhang; Zhuo Zhang; Gang Xing; Xuan Wang; Minghua Liu
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

6.  Biotinylated Bilirubin Nanoparticles as a Tumor Microenvironment-Responsive Drug Delivery System for Targeted Cancer Therapy.

Authors:  Yonghyun Lee; Soyoung Lee; Sangyong Jon
Journal:  Adv Sci (Weinh)       Date:  2018-04-24       Impact factor: 16.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.